VERAXA Biotech Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (“bsADC”) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb. The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.

Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products. The full press release can be accessed at https://ibn.fm/qMRuJ.

This milestone is significant as it demonstrates progress in the application of OmniAb’s platform to generate bispecific antibodies, which could lead to more targeted cancer therapies with fewer side effects. The AND-gate approach requires the drug to bind to two different tumor antigens before being internalized and releasing its cytotoxic payload, potentially reducing off-target toxicity. For VERAXA, which is building a pipeline of next-generation antibody-based therapeutics including bispecific T cell engagers and ADCs, this advancement supports its strategy to leverage innovative formats for solid tumor treatment.

VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), and its BiTAC technology is a registered trademark. The company’s newsroom provides the latest updates at https://ibn.fm/VRXA.

Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. Investors should not rely unduly on these statements, which are based on information available as of the date hereof.